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Background A significant proportion of people who cycle through prisons express a desire to quit smoking, yet smoking rates in this population are two to four times higher than in the general community. Smoking cessation pharmacotherapy (SCP) is an important component of evidence-based cessation support, yet no studies have examined use of this pharmacotherapy after release from prison. Methods We linked data from a survey of 971 smokers who were within 8 weeks of release from prison in Queensland, Australia, with federal Pharmaceutical Benefits Scheme (PBS) records for the 2 years after release, to identify subsidised use of SCP (varenicline, bupropion and nicotine patches). We used Cox proportional hazards regression to identify independent predictors of SCP use. Findings According to PBS data, 86 participants (8.9%) accessed SCP in the 2 years following release from prison. Participants who were aged 25 years or older (HR 2.51, 95% CI 1.19 to 5.31), employed before prison (HR 1.93, 95% CI 1.14 to 3.28), highly nicotine dependent at baseline (HR 2.21, 95% CI 1.23 to 3.97) and using non-psychotropic medications in prison (HR 2.29, 95% CI 1.24 to 4.22) were more likely to use subsidised SCP during follow-up. Conclusion Despite a very high rate of tobacco use among people cycling through prisons and the very low cost of (subsidised) SCP in Australia, few exprisoners obtain pharmaceutical assistance with quitting smoking. Policy attention needs to focus on supporting former prisoners to access SCP, to reduce the high rate of tobacco-related morbidity and mortality in this profoundly marginalised population.
BACkground
Prisoners smoke tobacco at a rate of between two and four times the non-incarcerated population, 1-4 yet the majority report a desire to quit. 2 5 These high levels of tobacco use exacerbate prisoners' already increased age-adjusted mortality and morbidity, 2 6 potentiate symptoms of mental disorder 7 8 and compound financial disadvantage. 5 In an attempt to reduce tobacco-related harms in this population, tobacco smoking has been fully or partially banned in correctional facilities in some countries. [9] [10] [11] [12] [13] While these bans may result in some health benefits, 9 smoking abstinence is often temporary, with the majority relapsing on the day of release. 14 15 The time following release from prison is marked by a decline in physical 6 16-20 and mental 21 22 health for many ex-prisoners. Interventions to promote long-term smoking cessation after release from prison are urgently required.
Smoking cessation pharmacotherapy (SCP) including nicotine replacement therapy (NRT) 23 24 and prescription-only medications varenicline and bupropion [25] [26] [27] is recognised for its effectiveness in assisting with smoking cessation. A recent review confirmed the effectiveness of pharmacotherapy in helping prisoners maintain smoking cessation. 28 In Australia, although NRT is available for over-thecounter purchase, nicotine patches, bupropion and varenicline are available by prescription through the Pharmaceutical Benefits Scheme (PBS), which provides medications to Australians at a federal government-subsidised price, with further discounts to concessional users on low incomes. 29 30 The Australian healthcare system provides universal free or subsidised healthcare services to its citizens, 31 and rates favourably in terms of efficiency, quality, and access to care and medication compared with many other developed countries. 32 33 Although prisoners in Australia are unable to access PBS-subsidised medications, 34 once they are released from prison these medications are typically available at very low cost; for example, concessional PBS users (including most former prisoners) can access varenicline for $A6.20, compared with $A38.30 for other PBS users and $A109.55 for non-PBS users. 30 35 Only one study has examined predictors of NRT adherence in prison, with identified predictors being greater prior daily smoking level and more previous quit attempts. 36 No studies have measured use of SCP after release from prison, such that neither the uptake nor the characteristics of those who access SCP after release from prison are known. In a large cohort of adult smokers released from prison, the aim of this study was to document the incidence and identify predictors of prescribed nicotine patch, varenicline and bupropion use.
MeThod study overview
This paper involves secondary analysis of data from a randomised controlled trial of the Passports intervention, designed to increase access to healthcare in adults released from prisons in Queensland, Australia. 37 38 Baseline data were collected in seven prisons between August 2008 and July 2010 from adults who expected to be released within the next 6 weeks. Participant identities were linked prospectively with correctional, health and mortality records for 2 years after release. Reincarceration data from Queensland Corrective Services were linked deterministically based on a unique prisoner identification number. PBS records for the cohort were obtained through probabilistic data linkage based on name, sex, date of birth and any aliases. We identified deaths in the sample through probabilistic linkage with the National Death Index.
sample
From an initial sample of 1325 participants, we removed 288 non-smokers (measured by self-reported smoking status at baseline), 65 inmates not released within 8 weeks of baseline interview and one participant for whom data could not be linked.
The sample for analysis was composed of 971 participants who were released from prison during the study.
Measures

Outcome variable-SCP access
We searched PBS claims data for first dispensing of SCP within 2 years of release from prison. SCP options available on the PBS include nicotine patches (ATC code N07BA01), varenicline (ATC code N07BA03) and bupropion (ATC code N06A×12). 30 
Baseline measures
We examined potential predictors of SCP uptake across six domains: sociodemographic, criminal justice, substance abuse, 
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mental health, physical health and social/reintegration support. An additional variable controlled for the impact of the Passports intervention. Exposed and unexposed categories for each variable, and the data source, are described in the online supplementary table S1.
statistical analyses
We performed univariate and multivariate Cox regression analyses with time to first SCP access as the outcome. The period of observation for each participant spanned from date of release from prison until first nicotine patch, varenicline or bupropion supply, death or 2 years after release. To account for episodes of reincarceration during follow-up (where PBS subsidies are unavailable), we removed days in prison from time at risk. Analyses were performed using Stata V. 13.1. 
resulTs
A total of 86 (8.9%) participants were supplied PBS-subsidised SCP during a median of 22.1 months (IQR 14.8-24 months) of community follow-up. This equates to a supply rate of 5.7 per 100 person-years. SCP types for first supply postrelease included varenicline (n=78), nicotine patches (n=5) and bupropion (n=3). Table 1 shows the percentage of participants who accessed SCP within the follow-up period according to baseline characteristics, and the unadjusted and adjusted hazard of SCP access according to baseline characteristics. The Passports intervention had no effect on SCP access (p>0.05), and so was excluded from the adjusted model to preserve statistical power. In the adjusted model, variables significantly associated with SCP supply included being aged 25 years or older (figure 1), being employed before prison, being highly nicotine dependent at baseline and using non-central nervous system (CNS) medications at baseline.
dIsCussIon
In a large cohort of adult smokers followed prospectively from prison into the community, we found that fewer than one in 10 was supplied with subsidised SCP over a period of 2 years, despite many likely having a desire to quit 2 5 and SCP being available at very low cost. Although there are no comparable national data, one population-wide study of Australian smokers 39 found that 52.2% had ever used any form of SCP. There is a clear and pressing need to identify and eliminate barriers to SCP uptake, to reduce rates of smoking and related morbidity in this highly vulnerable population.
Consistent with population studies, we found that SCP uptake was greater for those employed before prison 40 41 and for those aged 25 years or older, 36 39 42-44 an unfortunate finding considering that younger smokers benefit most from cessation. 45 46 Furthermore, individuals taking medication for physical health conditions (non-CNS medications) in prison were more likely to be supplied with SCP, perhaps mediated by greater contact with health professionals for ongoing management of other medication needs. 47 To the extent that this is the case, it is notable that we found no association between use of psychotropic medications and SCP uptake. This may reflect diagnostic overshadowing, 48 with physicians focussing on the management of mental illness to the detriment of other health problems. 49 Participants who used cannabis and methamphetamine at risky levels before prison were less likely to be supplied with SCP after release from prison, although these associations were attenuated to the null in multivariate analyses. Other studies have shown that patterns of substance use before prison are strongly predictive of substance use after release from prison. [50] [51] [52] [53] Efforts to promote tobacco cessation in ex-prisoners and other populations with a high prevalence of co-occurring illicit substance use should provide co-ordinated, evidence-based treatment for both substances. 54 55 Our findings highlight a clear need to improve uptake of SCP in ex-prisoners, but it remains unclear how best to achieve this. Based on a previous review of the literature and informed by our own findings, we recommend a cohesive policy and practice shift that focuses on (1) improving ex-prisoners' knowledge of SCP's effectiveness and accessibility and (2) increasing contact with primary care after release from prison. Primary care physicians have a crucial role to play in improving the health of ex-prisoners 56 57 and can improve abstinence rates and motivate quit attempts, 58 59 especially in patients with complex health and welfare needs. 36 Providing access to PBS-subsided medication in prison may also improve SCP uptake in this population. 60 As prisoners typically experience improved health while incarcerated, 2 61 62 the provision of SCP in prison, even for time periods as short as 3 weeks, 23 could assist prisoners in maintaining their improved health postrelease 34 60 through the reduction of physiological and psychomotor withdrawal symptoms experienced during quit attempts. rates of primary care contact in this population are roughly twice as high as in the age-matched and sex-matched general population, and a large proportion of contacts results in a prescription being filled. 64 Third, we relied on self-report for measurement of most baseline variables. However, there is growing evidence that self-reported health information in incarcerated populations can be reliable.
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ConClusIon
The majority of people who cycle through prisons smoke, and many wish to quit. Even in the context of government subsidised SCP, only a small proportion of ex-prisoners accessed subsidised SCP in the 2 years following release from prison. Our findings highlight a missed opportunity to improve health outcomes for this marginalised and underserved population. Further research is required to identify barriers to SCP uptake following release from prison.
What this paper adds
What is known on this topic? ► The vast majority of prisoners smoke tobacco, and people who cycle through prisons are at increased risk of smokingrelated morbidity and mortality. Smoking cessation pharmacotherapy (SCP), recognised for its effectiveness in assisting with smoking cessation, is available at a heavily subsidised rate in the Australian community. ► No studies have examined use of SCP after release from prison.
What this study adds?
► Only a small proportion of smokers released from prison accessed SCP, pointing to a missed opportunity to reduce smoking in this vulnerable population. ► Those who were aged 25 years or older, were employed before prison, used non-central nervous system medications in prison and were heavily nicotine dependent were more likely to access subsidised SCP following release from prison.
